| Name | Title | Contact Details |
|---|
Veteran Benefits Guide (VBG) is a benefit advisory company dedicated to assisting U.S. Armed Forces Veterans in maximizing their VA disability compensation ratings and benefits. Founded by Joshua Smith, a former Marine and VA rater, VBG provides pre-filing and post-filing consulting services. The company is headquartered in Las Vegas, Nevada, and has experienced significant growth since its inception in 2019. VBG employs a team of trained case managers, many of whom have backgrounds in the VA, to offer personalized guidance through the claims process. Their services include comprehensive reviews of military records, tailored claim strategies, and support for filing claims independently. VBG utilizes proprietary software to streamline the claims process and has a strong track record, boasting a 90% client success rate for favorable VA decisions and a perfect 5-star Google rating. The company emphasizes a Veteran-friendly approach, ensuring accuracy and efficiency in navigating the VAs Compensation & Pension process.
Stillwater Insurance Group is a national insurance provider offering a full suite of insurance products and services. We strive to be the most respected insurance provider in the United States by setting and achieving the highest standards in quality products, service, customer experience and claims satisfaction. Stillwater is: Smart - we meet the evolving needs for homeowners, auto and business insurance Fast - We exceed expectations for customer and claims service Strong - Were ready when needed to help our customers get back on their feet We have an A+ accreditation from the Better Business Bureau. This recognizes our commitment to transparency, responsiveness, integrity and delivering on the promises we make. And we have an A- (Excellent) rating from A.M. Best, the leading insurance rating organization.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.